supernus pharmaceuticals inc 2025年季度报告

For the quarterly period endedMarch 31, 2025 ORTRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES incorporation or organization)9715 Key West AvenueRockville pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). ☒YesNo☐Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,” and “emerging growth company” in Rule12b-2 of the Exchange Act.Large accelerated filer☒Accelerated filer☐Non-accelerated filer☐Smaller reporting company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section13(a)of the Exchange Act.o FOR THE QUARTERLY PERIOD ENDED March 31, 2025PARTI — FINANCIAL INFORMATION Condensed Consolidated Balance Sheets Condensed Consolidated Statements ofEarnings (Loss)Condensed Consolidated Statements of Comprehensive Earnings (Loss) Condensed Consolidated Statements of Changes in Stockholders' Equity Item3. Defaults Upon Senior SecuritiesItem4. Mine Safety Disclosures Item6. ExhibitsSIGNATURES2 The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with therequirements of the U.S. Securities and Exchange Commission (SEC) for interim financial information. As permitted under Generally Accepted Accounting Principles in the United States (U.S. GAAP), certain notes and other information have been omitted from theinterim unaudited condensed consolidated financial statements presented in this Quarterly Report on Form10-Q. Therefore, theseunaudited condensed consolidated financial statements should be read in conjunction with the Company’s most recent Annual Reporton Form10-K, for the year ended December31, 2024, filed with the SEC.In management’s opinion, the unaudited condensed consolidated financial statements include all normal and recurring The Company, which is primarily located in the U.S., operates inoneoperating segment.ReclassificationsThe prior year amounts related to the captionInventory valuation write-downin the condensed consolidated statements ofcash flows has been reclassified to conform to current year presentation. The reclassification did not affect the other condensedconsolidated financial statements. Consolidation The Company's unaudited condensed consolidated financial statements include the accounts of SupernusPharmaceuticals,Inc. and its wholly owned subsidiaries. These are collectively referred to herein as "Supernus" or "the Company."Supernus Pharmaceuticals, Inc. and each of its subsidiaries are distinct legal entities. All material intercompany transactions andbalances have been eliminated in consolidation.The unaudited condensed consolidated financial statements reflect the consolidation of entities in which the Company has a that most significantly impact the VIE's economic performance; and the obligation to absorb losses of, or the right to receive benefitsfrom the VIE that could potentially be significant to that VIE. The Company's judgment with respect to its level of influence or control Company is not the primary beneficiary of the VIE, and an ownership interest is maintained in the entity, the interest is accounted for under the equity or cost methods of accounting, as appropriate. The Company bases its estimates on: historical experience; forecasts; information received from its service providers;information from other sources, including public and proprietary sources; and other assumptions that the Company believes are Advertising Expense Advertising expense includes the cost of promotional materials and activities, such as printed materials and digital marketing,marketing programs and speaker programs. The cost of the Company's advertising efforts is expensed as incurred. approximately $24.3million for the three months ended March31, 2024, respectively. These expenses are recorded as a component ofSelling, general and administrative expensesin the unaudited condensed consolidated statements of earnings (loss).Insurance RecoveriesThe Company has several policies with third-party insurers that provide for the recovery of certain costs incurred by theCompany. The Company records our rights to insurance recoveries as a receivable when the respective costs are reimbursable underapplicable insurance policies, it is probable that such costs will be reimbursed, and reimbursement can be reasonably estimated. As Recently Issued Accounting Pronouncements Segment Disclosures (Topic 280).The new standard improves reportable segment disclosure requirements, primarily through enhanceddisclosures about significant segment expenses that are regularly provided to the chief operating decision maker. ASU 2023-07 also Note 13,S